{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:07:06Z","timestamp":1788264426316,"version":"build-2803163510"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Breast cancer is the most common cancer in women worldwide. Anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin) are among the most used drugs for the treatment of breast cancer. Unfortunately, anthracyclines cause cardiotoxicity, which is a limiting factor for its use, and the lifetime cumulative dose of anthracyclines is the major risk factor for cardiotoxicity. In our study, we focused on acute and subacute heart damage. One of the main factors is a genetic predisposition, which determines individual susceptibility to anthracycline cardiotoxicity. The main idea of this study was, for the first time, to evaluate drug metabolism-related genes as a risk factor for developing cardiovascular toxicity in breast cancer patients. The main objective of our study was to identify the impact of drug metabolism-related gene SNPs on the development of subclinical heart damage during and\/or after doxorubicin-based chemotherapy in breast cancer patients. The data of 81 women with breast cancer treated with doxorubicin-based chemotherapy in an outpatient clinic were analyzed, and SNP RT-PCR tests were performed. The drug metabolism-related gene variants SULT2B1 rs10426377, UGT1A6 rs17863783, CBR1 rs9024, CBR3 rs1056892, NCF4 rs1883112, and CYBA rs1049255 did not reach a statistically important impact on ABCC in multivariate logistic regression analysis. However, we identified that NCF4 rs1883112 had a risk reduction tendency for ABCC (OR = 0.49, 95% CI 0.27\u20130.87, p = 0.015). Our findings suggest that some SNPs, such as NCF4 rs1883112, may be associated with a reduced risk of cardiotoxicity, while no variants in this study showed a statistically significant increased risk. Even though, NCF4 rs1883112 showed a risk reduction tendency, suggesting the potential for personalized risk stratification. We can conclude that multiple genes are involved in ABCC, with different impacts, and it is unlikely that there is a single driver gene in ABCC pathogenesis.<\/jats:p>","DOI":"10.3390\/ijms26094051","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:08:24Z","timestamp":1745554104000},"page":"4051","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-4475","authenticated-orcid":false,"given":"Domas","family":"Vaitiekus","sequence":"first","affiliation":[{"name":"Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintare","family":"Muckiene","sequence":"additional","affiliation":[{"name":"Clinical Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-745X","authenticated-orcid":false,"given":"Dovydas","family":"Verikas","sequence":"additional","affiliation":[{"name":"Laboratory for Automation of Cardiovascular Investigation, Institute of Cardiology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrone","family":"Vaitiekiene","sequence":"additional","affiliation":[{"name":"Clinical Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skaiste","family":"Astasauskaite","sequence":"additional","affiliation":[{"name":"Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolandas","family":"Gerbutavicius","sequence":"additional","affiliation":[{"name":"Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-2032","authenticated-orcid":false,"given":"Agne","family":"Bartnykaite","sequence":"additional","affiliation":[{"name":"Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Ugenskien\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaldas","family":"Jurkevi\u010dius","sequence":"additional","affiliation":[{"name":"Clinical Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-7786","authenticated-orcid":false,"given":"Elona","family":"Juozaityt\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.ejca.2007.05.014","article-title":"Childhood and adolescent cancer survival: A period analysis of data from the Canadian Cancer Registry","volume":"43","author":"Ellison","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e000665","DOI":"10.1161\/JAHA.113.000665","article-title":"Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e006798","DOI":"10.1161\/CIRCHEARTFAILURE.119.006798","article-title":"Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure","volume":"13","author":"Kamiya","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes\u2014A report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Al-Otaibi, T.K., Weitzman, B., Tahir, U.A., and Asnani, A. (2022). Genetics of Anthracycline-Associated Cardiotoxicity. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.867873"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0076-6879(05)00004-2","article-title":"UDP-glucuronosyltransferase 1A6: Structural, functional, and regulatory aspects","volume":"400","author":"Bock","year":"2005","journal-title":"Methods Enzymol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/jpet.107.122895","article-title":"Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: Gene sequence variation and functional genomics","volume":"322","author":"Ji","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0090-9556(25)00245-4","article-title":"Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography","volume":"8","author":"Andrews","year":"1980","journal-title":"Drug Metab. Dispos."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0009-2797(00)00196-4","article-title":"Carbonyl reductase","volume":"129","author":"Forrest","year":"2000","journal-title":"Chem. Biol. Interact."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pgs.14.179","article-title":"Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma","volume":"16","author":"Reichwagen","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s11845-017-1601-4","article-title":"Association analysis of rs1049255 and rs4673 transitions in p22phox gene with coronary artery disease: A case-control study and a computational analysis","volume":"186","author":"Mazaheri","year":"2017","journal-title":"Ir. J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.molmed.2017.03.004","article-title":"ROS in Cancer: The Burning Question","volume":"23","author":"Chio","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/sqb.2016.81.030791","article-title":"Cancer, Oxidative Stress, and Metastasis","volume":"81","author":"Gill","year":"2016","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/VHRM.S165173","article-title":"Paraoxonase (PON)-1: A brief overview on genetics, structure, polymorphisms and clinical relevance","volume":"14","author":"Shunmoogam","year":"2018","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1210\/jcem.82.7.4096","article-title":"Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus","volume":"82","author":"Odawara","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-013-1665-z","article-title":"The Q192R polymorphism of the paraoxonase 1 gene is a risk factor for coronary artery disease in Saudi subjects","volume":"380","author":"Hassan","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1747-4949.2012.00813.x","article-title":"PON gene polymorphisms and ischaemic stroke: A systematic review and meta analysis","volume":"8","author":"Liu","year":"2013","journal-title":"Int. J. Stroke"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Geng, R., Chen, Z., Zhao, X., Qiu, L., Liu, X., Liu, R., Guo, W., He, G., Li, J., and Zhu, X. (2014). Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0116027"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2013.01.036","article-title":"A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis","volume":"228","author":"Liu","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1159\/000487565","article-title":"Functional SNP in the 3\u2032UTR of PON1 is Associated with the Risk of Calcific Aortic Valve Stenosis via MiR-616","volume":"45","author":"Wang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1159\/000491062","article-title":"Identification of Prognostic Value of Rs3735590 Polymorphism in 3\u2032-Untranslated Region (3\u2032-UTR) of Paraoxonase 1 (PON-1) in Chronic Obstructive Pulmonary Disease Patients who Received Coronary Artery Bypass Grafting (CABG)","volume":"47","author":"Lv","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.5414\/CP202500","article-title":"Relationship of microRNA 616 gene polymorphism with prognosis of patients with premature coronary artery disease","volume":"54","author":"Zhang","year":"2016","journal-title":"Int. J. Clin. Pharmacol Ther."},{"key":"ref_32","unstructured":"(2008). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Principles and Practice of Clinical Trial Medicine, Elsevier."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bbmt.2016.02.017","article-title":"Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors","volume":"22","author":"Leger","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/cncr.28256","article-title":"Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia","volume":"119","author":"Lipshultz","year":"2013","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/cncr.23534","article-title":"Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer","volume":"112","author":"Blanco","year":"2008","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/pgs.15.162","article-title":"Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines","volume":"17","author":"Hertz","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","article-title":"Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"27","author":"Serie","year":"2017","journal-title":"Pharmacogenet. Genom."},{"key":"ref_38","first-page":"1271","article-title":"Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome","volume":"31","author":"Ferguson","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13318-019-00592-6","article-title":"Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: An Analysis from the \u201cEuropean Paediatric Oncology Off-patents Medicines Consortium\u201d (EPOC)","volume":"45","author":"Hellmann","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ng0295-202","article-title":"Mouse model of X\u2013linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production","volume":"9","author":"Pollock","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/01.HYP.0000158845.49943.5e","article-title":"Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase","volume":"45","author":"Touyz","year":"2005","journal-title":"Hypertension"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8863789","DOI":"10.1155\/2021\/8863789","article-title":"Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies","volume":"2021","author":"Carrasco","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_43","first-page":"5158","article-title":"Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice","volume":"60","author":"Forrest","year":"2000","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1634\/theoncologist.2012-0239","article-title":"Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms","volume":"18","author":"Cascales","year":"2013","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4051\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:21:11Z","timestamp":1760030471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/9\/4051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26094051"],"URL":"https:\/\/doi.org\/10.3390\/ijms26094051","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}